explore -WSS

explore

author：leisure time 2025-09-29 20:52:21 - browse：473

Slayman with (left to right) Dr. Leo Riella, Medical Director of Kidney Transplantation, Dr. Nahel Elias, Interim Chief, Division of Transplant Surgery, his partner, Faren, and Dr. Tatsuo Kawai, Director, Legorreta Center for Clinical Transplant Tolerance. -- HEALTH coverage from STAT — Rick Slayman, holding hands with his partner, Faren, poses with members of his Massachusetts General Hospital medical team before being going home last month. Michelle Rose/Massachusetts General Hospital

Rick Slayman, the first man to receive a kidney transplant from a genetically engineered pig, has died, according to a statement from his family and Massachusetts General Hospital, where he underwent the historic operation in March.

“Our family is deeply saddened about the sudden passing of our beloved Rick but take great comfort knowing he inspired so many,” his family said in the statement released Saturday evening.

The hospital did not say how or when Slayman died. A spokesperson declined to provide further information, citing “privacy issues.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout LOUD podcast: How biotech is using artificial intelligence

WSS

How digital tools helped lower hypertension in marginalized patients

Readout LOUD podcast: How biotech is using artificial intelligence

Why we need to separate burnout from moral injury in health care

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Biden report: The neurospychology of memory and aging

In areas with more Black doctors, Black people live longer

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Supreme Court strikes down use of affirmative action

Why are elite athletes different? Take a look at their microbes

Hepatitis C has a cure — but many Americans still lack access to it

How digital tools helped lower hypertension in marginalized patients

As demand for Covid shots wanes, Moderna seeks its next success

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Guidelines to prevent youth baseball injuries need more muscle

Biogen Alzheimer’s drug launch off to slow start

hotspot

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Do masks work? RCTs can't tell us

Gilead might be held responsible for not developing a drug

Medicare threatens to cut off funding for HCA's Mission hospital

How digital tools helped lower hypertension in marginalized patients

Donald Trump's relentless attacks on special counsel Jack Smith

explore

Wikipedia

focus

focus